Cohance Lifesciences Limited
COHANCE · 543064 · Healthcare · Pharmaceuticals
- Market cap
- Rs 18,416 Cr
- P/E
- No data: the source has not published this figure.
- P/B
- 8.35x
- 52W high / low
- Rs 830 / Rs 266.7
Stored market cap (1.84163e+11) diverges from price x shares outstanding (1.22535e+13) by >3x; likely a stale or share-count-corrupted figure. Our computed roe (3.79%) diverges from BSE's own published figure (8.05%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong. Our computed net_margin (2.73%) diverges from BSE's own published figure (0.39%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong.
About Cohance Lifesciences
Cohance Lifesciences Limited is listed on the NSE under the symbol COHANCE and on the BSE under scrip code 543064. It is classified in the Healthcare sector, industry: Pharmaceuticals. It is a constituent of BSE 500, NIFTY 500 and NIFTY Smallcap 250. The company listed on 9 Mar 2020 and has a face value of Rs 1.
The latest available end-of-day price is Rs 481.35 (+1.11% on the day), for a market capitalisation of Rs 18,416 Cr. Price-to-book is 8.35x. The 52-week range is Rs 266.7 to Rs 830. The latest price is 38% of the way from the 52-week low to the 52-week high.
Latest annual results
For Q1 FY27 (period ended 30 Jun 2026), Cohance Lifesciences Limited reported revenue of Rs 422 Cr, net profit of Rs -45.2 Cr and earnings per share of Rs -1.18.
On a trailing-twelve-month basis the filings add up to revenue of Rs 2,142 Cr, net income of Rs 58.5 Cr and a net margin of 2.73%.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, Cohance Lifesciences Limited's ownership is split: promoters 57.48%; foreign institutional investors (FIIs) 7.71%; domestic institutional investors (DIIs) 18.86%; retail and other shareholders 15.95%.
Compared with the filing for 30 Jun 2026: promoter holding −0.01 percentage points; FII holding +1.21 percentage points; DII holding −1.23 percentage points.
The same filing lists reported promoter pledge of 94.56% and 93,846 shareholders on record.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Companies related to Cohance Lifesciences
Other Healthcare companies of a similar market capitalisation
- Granules India LimitedGRANULES · Market cap Rs 20,750 Cr
- Caplin Point Laboratories LimitedCAPLIPOINT · Market cap Rs 18,058 Cr
- Onesource Specialty Pharma LimitedONESOURCE · Market cap Rs 17,994 Cr
- Pfizer LimitedPFIZER · Market cap Rs 17,201 Cr
- Eris Lifesciences LimitedERIS · Market cap Rs 16,139 Cr
- Syngene International LimitedSYNGENE · Market cap Rs 16,091 Cr
- Vijaya Diagnostic Centre LimitedVIJAYA · Market cap Rs 15,066 Cr
- Jubilant Pharmova LimitedJUBLPHARMA · Market cap Rs 14,947 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.